Cover Image
市場調查報告書

紫質症 (紅血球合成性紫質症):開發中產品分析

Porphyria (Erythropoietic Protoporphyria) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 360908
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
紫質症 (紅血球合成性紫質症):開發中產品分析 Porphyria (Erythropoietic Protoporphyria) - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 63 Pages
簡介

本報告提供紫質症 (紅血球合成性紫質症的)治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

紫質症 (紅血球合成性紫質症)概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

紫質症 (紅血球合成性紫質症):企業開發中的治療藥

紫質症 (紅血球合成性紫質症):大學/機關研究中的治療藥

紫質症 (紅血球合成性紫質症):開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

紫質症 (紅血球合成性紫質症):企業開發中的產品

紫質症 (紅血球合成性紫質症):大學/機關研究中的產品

紫質症 (紅血球合成性紫質症的)治療藥的開發企業

  • Alnylam Pharmaceuticals, Inc.
  • Clinuvel Pharmaceuticals Limited
  • Digna Biotech, S.L.
  • UniQure N.V.

紫質症 (紅血球合成性紫質症):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

紫質症 (紅血球合成性紫質症):最近的開發平台趨勢

紫質症 (紅血球合成性紫質症):開發中止的產品

紫質症 (紅血球合成性紫質症):產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8088IDB

Summary

Global Markets Direct's, 'Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016', provides an overview of the Porphyria (Erythropoietic Protoporphyri) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Porphyria (Erythropoietic Protoporphyri) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Porphyria (Erythropoietic Protoporphyri)
  • The report reviews pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Porphyria (Erythropoietic Protoporphyri) therapeutics and enlists all their major and minor projects
  • The report assesses Porphyria (Erythropoietic Protoporphyri) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Porphyria (Erythropoietic Protoporphyri)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Porphyria (Erythropoietic Protoporphyri) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Porphyria (Erythropoietic Protoporphyri) Overview
  • Therapeutics Development
    • Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Overview
    • Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis
  • Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Development by Companies
  • Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Investigation by Universities/Institutes
  • Porphyria (Erythropoietic Protoporphyri) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Porphyria (Erythropoietic Protoporphyri) - Products under Development by Companies
  • Porphyria (Erythropoietic Protoporphyri) - Products under Investigation by Universities/Institutes
  • Porphyria (Erythropoietic Protoporphyri) - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Clinuvel Pharmaceuticals Limited
    • Digna Biotech, S.L.
    • UniQure N.V.
  • Porphyria (Erythropoietic Protoporphyri) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • afamelanotide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALN-AS1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AMT-021 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DB-027 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Enzyme Replacement Therapy for Acute Intermittent Porphyria - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Porphyria (Erythropoietic Protoporphyri) - Recent Pipeline Updates
  • Porphyria (Erythropoietic Protoporphyri) - Discontinued Products
  • Porphyria (Erythropoietic Protoporphyri) - Product Development Milestones
    • Featured News & Press Releases
      • Mar 24, 2016: NICE's technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria
      • Feb 16, 2016: Clinuvel brief on European commercialisation
      • Feb 12, 2016: SCENESSE receives US FDA orphan designation for cutaneous porphyrias
      • Sep 15, 2015: Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 for the Treatment of Acute Hepatic Porphyrias
      • Aug 27, 2015: FDA grants Clinuvel a Type C Meeting
      • Jul 02, 2015: New England Journal of Medicine publishes pivotal Phase III SCENESSE studies
      • Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity
      • Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity
      • Jun 05, 2015: SCENESSE Commercialisation Update
      • May 26, 2015: Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Porphyria (Erythropoietic Protoporphyri), H1 2016
  • Number of Products under Development for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Porphyria (Erythropoietic Protoporphyri) - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Porphyria (Erythropoietic Protoporphyri) - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2016
  • Porphyria (Erythropoietic Protoporphyri) - Pipeline by Digna Biotech, S.L., H1 2016
  • Porphyria (Erythropoietic Protoporphyri) - Pipeline by UniQure N.V., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Porphyria (Erythropoietic Protoporphyri) Therapeutics - Recent Pipeline Updates, H1 2016
  • Porphyria (Erythropoietic Protoporphyri) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Porphyria (Erythropoietic Protoporphyri), H1 2016
  • Number of Products under Development for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top